Gujarat Themis Biosyn Ltd Business Overview - SOIC x StockScans Report

as of Jul 2026

Business segments

A single fermentation engine that has evolved into three stages of vertical integration - intermediates today, APIs tomorrow, and a global branded portfolio the day after - with a Japanese biotech acquisition adding an entirely new CDMO dimension.

1. Fermentation-based intermediates: the scarce core that everything else is built on

GTBL makes Rifamycin S and Rifamycin O through fermentation - a capability so rare in India that only a handful of companies remain, while most of the country’s needs are met by imports.

2. API forward integration: moving one step closer to the finished pill

A new multi-purpose API plant at the same Vapi site began commercial production in May 2025, designed to convert GTBL’s own intermediates into active pharmaceutical ingredients for both domestic and export markets.

3. Sanofi brand portfolio: a ready-made global front end

In April 2026, GTBL agreed to buy 13 established branded generic anti-TB and anti-infective products from Sanofi for EUR 158 million - giving it instant access to pharmacy shelves across more than 55 countries without buying a single factory.

4. MicroBiopharm Japan: a fermentation CDMO platform with biotech depth

In May 2026, GTBL agreed to acquire 100% of MicroBiopharm Japan - a company that has been serving the world’s top six pharma companies for over 20 years - adding oncology APIs, plasmid DNA, and enzyme-based manufacturing to its toolkit.

Hybrid renewable power

An 18 MW captive wind-solar hybrid plant in Gujarat is being built to lower power costs and reduce dependence on the grid - a cost-saving infrastructure play, not a standalone business.

Group structure and partners

GTBL was born as a government joint venture with South Korean technology, but a series of structural moves - the exit of its Korean partner, an aborted merger with its sister company, and two transformative 2026 acquisitions - have reshaped it into an independent, globally ambitious fermentation platform.